Journal issues > Issue 5, September 2017 > Lung cancer screening programs: black or white?

Lung cancer screening programs: black or white?

By: E. Bustamante PhD, MSc, C. Soza-Ried PhD, MSc, C. Rolfo MD, PhD, L.E. Raez , V. Domínguez MD, E.S. Santos MD, C. Caglevic MD

SUMMARY

Lung cancer is a frequent malignancy worldwide with a high mortality rate. Most patients are diagnosed in advanced or metastatic stages that are not amenable to curative treatments, resulting in a poor overall survival rate. Screening programs could provide a solution to this problem, but it is unclear whether the great cost and possible risks that patients must face justify their implementation for lung cancer. This manuscript aims to show the published evidence related to screening programs for lung cancer and the importance and challenges of developing such programs in Latin America.

(BELG J MED ONCOL 2017;11(5):242–248)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top